Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SCLN's Cash to Debt is ranked higher than
98% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. SCLN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SCLN' s Cash to Debt Range Over the Past 10 Years
Min: 2.83  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.82
SCLN's Equity to Asset is ranked higher than
82% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. SCLN: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
SCLN' s Equity to Asset Range Over the Past 10 Years
Min: 0.52  Med: 0.82 Max: 0.92
Current: 0.82
0.52
0.92
Interest Coverage No Debt
SCLN's Interest Coverage is ranked higher than
98% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. SCLN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SCLN' s Interest Coverage Range Over the Past 10 Years
Min: 34.65  Med: 108.05 Max: 541.33
Current: No Debt
34.65
541.33
F-Score: 7
Z-Score: 7.45
M-Score: -2.59
WACC vs ROIC
15.80%
29.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.35
SCLN's Operating margin (%) is ranked higher than
64% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. SCLN: 13.35 )
Ranked among companies with meaningful Operating margin (%) only.
SCLN' s Operating margin (%) Range Over the Past 10 Years
Min: -30.5  Med: 6.16 Max: 26.31
Current: 13.35
-30.5
26.31
Net-margin (%) 13.12
SCLN's Net-margin (%) is ranked higher than
74% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. SCLN: 13.12 )
Ranked among companies with meaningful Net-margin (%) only.
SCLN' s Net-margin (%) Range Over the Past 10 Years
Min: -27.22  Med: 7.40 Max: 24.77
Current: 13.12
-27.22
24.77
ROE (%) 12.69
SCLN's ROE (%) is ranked higher than
67% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. SCLN: 12.69 )
Ranked among companies with meaningful ROE (%) only.
SCLN' s ROE (%) Range Over the Past 10 Years
Min: -19.53  Med: 7.07 Max: 30.21
Current: 12.69
-19.53
30.21
ROA (%) 10.77
SCLN's ROA (%) is ranked higher than
78% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. SCLN: 10.77 )
Ranked among companies with meaningful ROA (%) only.
SCLN' s ROA (%) Range Over the Past 10 Years
Min: -16.41  Med: 5.67 Max: 25.6
Current: 10.77
-16.41
25.6
ROC (Joel Greenblatt) (%) 85.54
SCLN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. SCLN: 85.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SCLN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -94.04  Med: 37.33 Max: 99.43
Current: 85.54
-94.04
99.43
Revenue Growth (3Y)(%) 3.50
SCLN's Revenue Growth (3Y)(%) is ranked lower than
59% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SCLN: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SCLN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.7  Med: 18.65 Max: 122.4
Current: 3.5
-4.7
122.4
EBITDA Growth (3Y)(%) -2.40
SCLN's EBITDA Growth (3Y)(%) is ranked lower than
64% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SCLN: -2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SCLN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.8  Med: -11.10 Max: 13.5
Current: -2.4
-53.8
13.5
EPS Growth (3Y)(%) -0.80
SCLN's EPS Growth (3Y)(%) is ranked lower than
60% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. SCLN: -0.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SCLN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.4  Med: -10.20 Max: 151
Current: -0.8
-59.4
151
» SCLN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SCLN Guru Trades in Q1 2015

Jim Simons 440,400 sh (+120.84%)
Chuck Royce 5,000 sh (unchged)
Paul Tudor Jones 35,055 sh (-14.86%)
» More
Q2 2015

SCLN Guru Trades in Q2 2015

Jim Simons 691,660 sh (+57.05%)
Chuck Royce 5,000 sh (unchged)
Paul Tudor Jones 28,310 sh (-19.24%)
» More
Q3 2015

SCLN Guru Trades in Q3 2015

Ken Fisher 398,426 sh (New)
Paul Tudor Jones 85,471 sh (+201.91%)
Chuck Royce 5,000 sh (unchged)
Jim Simons 443,500 sh (-35.88%)
» More
Q4 2015

SCLN Guru Trades in Q4 2015

Ken Fisher 484,848 sh (+21.69%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.88
SCLN's P/E(ttm) is ranked higher than
63% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.80 vs. SCLN: 21.88 )
Ranked among companies with meaningful P/E(ttm) only.
SCLN' s P/E(ttm) Range Over the Past 10 Years
Min: 6.29  Med: 17.63 Max: 189.41
Current: 21.88
6.29
189.41
Forward P/E 13.85
SCLN's Forward P/E is ranked higher than
60% of the 403 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.75 vs. SCLN: 13.85 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.78
SCLN's PE(NRI) is ranked higher than
67% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.83 vs. SCLN: 21.78 )
Ranked among companies with meaningful PE(NRI) only.
SCLN' s PE(NRI) Range Over the Past 10 Years
Min: 6.32  Med: 17.54 Max: 280
Current: 21.78
6.32
280
P/B 2.55
SCLN's P/B is ranked lower than
51% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. SCLN: 2.55 )
Ranked among companies with meaningful P/B only.
SCLN' s P/B Range Over the Past 10 Years
Min: 0.82  Med: 2.11 Max: 6.15
Current: 2.55
0.82
6.15
P/S 2.85
SCLN's P/S is ranked lower than
51% of the 937 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. SCLN: 2.85 )
Ranked among companies with meaningful P/S only.
SCLN' s P/S Range Over the Past 10 Years
Min: 0.67  Med: 2.41 Max: 12.41
Current: 2.85
0.67
12.41
PFCF 14.63
SCLN's PFCF is ranked higher than
79% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.80 vs. SCLN: 14.63 )
Ranked among companies with meaningful PFCF only.
SCLN' s PFCF Range Over the Past 10 Years
Min: 3.83  Med: 15.16 Max: 458
Current: 14.63
3.83
458
POCF 13.90
SCLN's POCF is ranked higher than
72% of the 631 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.19 vs. SCLN: 13.90 )
Ranked among companies with meaningful POCF only.
SCLN' s POCF Range Over the Past 10 Years
Min: 3.76  Med: 14.43 Max: 458
Current: 13.9
3.76
458
EV-to-EBIT 15.10
SCLN's EV-to-EBIT is ranked higher than
68% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.51 vs. SCLN: 15.10 )
Ranked among companies with meaningful EV-to-EBIT only.
SCLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.6  Med: 5.90 Max: 202.4
Current: 15.1
-24.6
202.4
EV-to-EBITDA 14.44
SCLN's EV-to-EBITDA is ranked higher than
62% of the 847 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.31 vs. SCLN: 14.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCLN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.1  Med: 5.60 Max: 51.1
Current: 14.44
-25.1
51.1
Shiller P/E 42.22
SCLN's Shiller P/E is ranked higher than
55% of the 170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.66 vs. SCLN: 42.22 )
Ranked among companies with meaningful Shiller P/E only.
SCLN' s Shiller P/E Range Over the Past 10 Years
Min: 34.2  Med: 61.64 Max: 590
Current: 42.22
34.2
590
Current Ratio 4.25
SCLN's Current Ratio is ranked higher than
76% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. SCLN: 4.25 )
Ranked among companies with meaningful Current Ratio only.
SCLN' s Current Ratio Range Over the Past 10 Years
Min: 1.32  Med: 5.65 Max: 12.05
Current: 4.25
1.32
12.05
Quick Ratio 3.91
SCLN's Quick Ratio is ranked higher than
78% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. SCLN: 3.91 )
Ranked among companies with meaningful Quick Ratio only.
SCLN' s Quick Ratio Range Over the Past 10 Years
Min: 1.05  Med: 5.21 Max: 11.4
Current: 3.91
1.05
11.4
Days Inventory 172.42
SCLN's Days Inventory is ranked lower than
73% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. SCLN: 172.42 )
Ranked among companies with meaningful Days Inventory only.
SCLN' s Days Inventory Range Over the Past 10 Years
Min: 171.31  Med: 222.46 Max: 278.93
Current: 172.42
171.31
278.93
Days Sales Outstanding 94.19
SCLN's Days Sales Outstanding is ranked lower than
63% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. SCLN: 94.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCLN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 80.45  Med: 111.65 Max: 148.37
Current: 94.19
80.45
148.37
Days Payable 56.53
SCLN's Days Payable is ranked lower than
63% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. SCLN: 56.53 )
Ranked among companies with meaningful Days Payable only.
SCLN' s Days Payable Range Over the Past 10 Years
Min: 46.87  Med: 94.63 Max: 159.4
Current: 56.53
46.87
159.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.30
SCLN's Price/Net Cash is ranked higher than
61% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.70 vs. SCLN: 6.30 )
Ranked among companies with meaningful Price/Net Cash only.
SCLN' s Price/Net Cash Range Over the Past 10 Years
Min: 2.06  Med: 5.45 Max: 344
Current: 6.3
2.06
344
Price/Net Current Asset Value 3.39
SCLN's Price/Net Current Asset Value is ranked higher than
77% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.29 vs. SCLN: 3.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SCLN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.93  Med: 3.81 Max: 53.57
Current: 3.39
0.93
53.57
Price/Tangible Book 3.01
SCLN's Price/Tangible Book is ranked higher than
59% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. SCLN: 3.01 )
Ranked among companies with meaningful Price/Tangible Book only.
SCLN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.84  Med: 3.59 Max: 17.88
Current: 3.01
0.84
17.88
Price/Projected FCF 1.00
SCLN's Price/Projected FCF is ranked higher than
87% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.16 vs. SCLN: 1.00 )
Ranked among companies with meaningful Price/Projected FCF only.
SCLN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.18 Max: 6.05
Current: 1
0.69
6.05
Price/Median PS Value 1.11
SCLN's Price/Median PS Value is ranked higher than
53% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. SCLN: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
SCLN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.72 Max: 138.8
Current: 1.11
0.26
138.8
Price/Graham Number 1.66
SCLN's Price/Graham Number is ranked higher than
65% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.18 vs. SCLN: 1.66 )
Ranked among companies with meaningful Price/Graham Number only.
SCLN' s Price/Graham Number Range Over the Past 10 Years
Min: 0.68  Med: 1.51 Max: 4.46
Current: 1.66
0.68
4.46
Earnings Yield (Greenblatt) (%) 6.56
SCLN's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SCLN: 6.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SCLN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 10.55 Max: 489.3
Current: 6.56
0.5
489.3

More Statistics

Revenue(Mil) $156
EPS $ 0.39
Beta1.86
Short Percentage of Float6.69%
52-Week Range $6.47 - 11.71
Shares Outstanding(Mil)49.38

Analyst Estimate

Dec15
Revenue(Mil)
EPS($) 0.57
EPS without NRI($) 0.57

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:SPJ.Germany,
SciClone Pharmaceuticals Inc is a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as a vaccine adjuvant according to the local regulatory approvals. It markets approximately 7 partnered and in-licensed products in China, including Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. The Company sells ZADAXIN in various international markets through its wholly owned subsidiary, SciClone Pharmaceuticals International Ltd. SPIL orders ZADAXIN from its European manufacturer and contracts with a third party for the storage of its finished goods inventory at warehousing facilities in Hong Kong. SPIL then distributes its product from these warehousing facilities based on purchase orders from its customers. ZADAXIN is manufactured in Europe by third parties under exclusive contract manufacturing and supply agreements. Its competitors include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.
» More Articles for SCLN

Headlines

Articles On GuruFocus.com
Profits in Motion: SciClone Pharmaceuticals (SCLN), Omega Protein (OME), Zoe's Kitchen (ZOES) Mar 12 2015 
Weekly CFO Sells Highlight: V, SCLN, VR, AMSG Jun 25 2012 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-K/A) Dec 06 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
SciClone Pharmaceuticals Inc. (SCLN) CEO Friedhelm Blobel buys 10,000 Shares May 26 2009 
SciClone Pharmaceuticals Inc. (SCLN) CFO Gary Titus buys 4,625 Shares May 26 2009 

More From Other Websites
SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : February 8,... Feb 08 2016
[$$] SciClone Launches Strategic Review Feb 04 2016
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 04 2016
SciClone Announces Final Resolution With The Securities And Exchange Commission And The Department... Feb 04 2016
SciClone To Present At BIO CEO & Investor Conference On February 9, 2016 Jan 27 2016
Soligenix Provides 2016 Business Outlook Reviews 2015 Achievements and 2016 Milestones Jan 26 2016
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 11 2016
SciClone Announces Preliminary 2015 Revenue Jan 11 2016
SciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 5,... Jan 05 2016
SciClone Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2... Dec 21 2015
Healthcare Sector Equities under the Scanner -- Zogenix, Amarin, SciClone Pharma, and PetMed Express Dec 18 2015
SCICLONE PHARMACEUTICALS INC Financials Dec 08 2015
SciClone To Present At 27th Annual Piper Jaffray Healthcare Conference On December 2, 2015 Dec 03 2015
Hedge Funds Aren’t Crazy About SciClone Pharmaceuticals, Inc. (SCLN) Anymore Nov 27 2015
What's Moving the Markets - Research on Aegean Marine, REX American Resources, SciClone and Blue... Nov 20 2015
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 17 2015
SciClone To Present At 27th Annual Piper Jaffray Healthcare Conference On December 2, 2015 Nov 17 2015
7 BioHealth Movers That Cannot Be Ignored Nov 14 2015
Moving Ahead of Averages, Technical Review - Research on Aegean Marine Petroleum Network, SciClone... Nov 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK